biotech / news / / The Manila Times
Haisco grants AbbVie the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland China, Hong Kong, and Macau.
Haisco granted AbbVie exclusive global rights to develop and commercialize pain medicines, excluding Greater China.
KEY POINTS
- The licensed compounds are at preclinical to Phase 1 stages in China and target pain-related indications.
- Haisco will receive a $30 million upfront payment and up to $715 million in milestone payments from AbbVie.
- Haisco is also eligible for tiered royalties on future net sales of the licensed pain medicines.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →